Lecture Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

E-Lert: Emerging Therapies for Advanced Prostate Cancer

Release Date: November 25, 2009| Expiration Date: November 25, 2010
0.5 AMA PRA Category 1 Credit(s)™| Nov 25, 2009, E-Lert

Lecture Overview

Treatment options for castration-resistant prostate cancer (CRPC) are limited, with a modest 3-month improvement in median overall survival with docetaxel-based chemotherapy, the current standard of care. At disease progression, there is no accepted salvage therapy. Patients frequently suffer significant and debilitating comorbidities resulting from the propensity of prostate cancer cells to metastasize to bone. Recently, a variety of agents, including epothilones, vaccines, endothelin A receptor antagonists, and androgen synthesis or signaling inhibitors, have shown activity in both first and subsequent lines of therapy for CRPC. A novel RANKL (receptor activator of nuclear factor-κB ligand) inhibitor has demonstrated efficacy in preventing bone complications in patients with prostate cancer. Clinical development of these agents is continuing in ongoing phase III trials.

The purpose of this activity is to update physicians on emerging therapies and ongoing clinical trials for the treatment of patients with advanced CRPC.

This educational activity is intended for medical oncologists involved in the care of patients with prostate cancer. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.

Upon completion of this educational activity, you should be able to:

  • Evaluate the safety and efficacy of new cytotoxic, endocrine, and targeted therapies for the treatment of patients with CRPC
  • Appraise novel bone-targeted therapies for patients with advanced prostate cancer

Interview With: Nancy Dawson, MD, FACP

Instructions for Participation

  1. Read the following information before entering the educational activity.
  2. Complete the Pretest.
  3. View the Flash video presentations and slides.
  4. Complete the Posttest.
  5. Answer the evaluation questions.
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.

You will be permitted 2 attempts to successfully complete the Posttest.

Complete the test(s) and evaluation by November 25, 2010 to receive your certificate online.

Read all of the conditions in the Activity Terms box below. You must accept the CME Activity Terms in order to continue:

Disclosure Policy
It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

Nancy Dawson, MD, FACP
Research Funding – Dendreon Corporation; Paid Consultant – Amgen; Speaker’s Bureau – AstraZeneca

PER Editorial Staff
No relevant relationships to disclose

This CME activity includes discussion of investigational and/or unlabeled uses of drugs, including the use of denosumab, abiraterone acetate, MDV3100, sipuleucel-T, zibotentan, and ixabepilone in advanced prostate cancer. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Commercial Support
An educational grant for this activity was provided by AstraZeneca.

Software Requirements
The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Additional software requirements include:

Macintosh Users
Compatible Web browsers include:

Additional software requirements include:

Disclaimer
The views and opinions expressed in this learning activity are those of the presenter and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the presenter and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

Privacy Policy
Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2009 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, E-Lert: Emerging Therapies for Advanced Prostate Cancer
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@cancerlearning.com

8701

Educational Grants

An educational grant for this activity was provided by:


  1. AstraZeneca